ABOUND.2L+: nab-paclitaxel (nab-P) +/- CC-486 or durvalumab in previously treated patients with advanced non-small cell lung cancer (NSCLC)
主要な著者: | Morgensztern, D, Ong, TJ, Dols, MC, Aix, SP, Postmus, PE, Lewanski, C, Bennouna, J, Fischer, JR, Vidal, OJ, Stewart, DJ, Fasola, G, Ardizoni, A, Weaver, J, Wolfsteiner, M, Talbot, D, Govindan, R |
---|---|
フォーマット: | Conference item |
出版事項: |
Oxford University Press
2017
|
類似資料
-
Nab-paclitaxel + durvalumab as second- or third-line treatment of advanced NSCLC: results from ABOUND.2l+
著者:: Govindan, R, 等
出版事項: (2017) -
Efficacy and safety of second- or third-line nab-paclitaxel + durvalumab in patients with advanced NSCLC (ABOUND.2L+)
著者:: Morgensztern, D, 等
出版事項: (2018) -
Quality of life in patients with advanced NSCLC treated in second- or third-line with nab-paclitaxel + durvalumab: abound.2l+
著者:: Talbot, D, 等
出版事項: (2018) -
nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+)
著者:: Daniel Morgensztern, 等
出版事項: (2021-02-01) -
ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin‐bound paclitaxel with or without CC‐486 as second‐line treatment for advanced nonsquamous non‐small cell lung cancer (NSCLC)
著者:: Morgensztern, D, 等
出版事項: (2018)